Published in Mol Pharm on December 06, 2010
Stimuli-responsive nanocarriers for drug delivery. Nat Mater (2013) 3.52
RGD-modified apoferritin nanoparticles for efficient drug delivery to tumors. ACS Nano (2013) 1.23
Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2012) 1.18
Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors. Cancer Res (2012) 1.12
Complete regression of local cancer using temperature-sensitive liposomes combined with ultrasound-mediated hyperthermia. J Control Release (2013) 0.93
Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments. Front Chem (2014) 0.93
Evaluation of doxorubicin-loaded 3-helix micelles as nanocarriers. Biomacromolecules (2013) 0.92
Phase-shift, stimuli-responsive drug carriers for targeted delivery. Ther Deliv (2011) 0.90
Ultrasonic enhancement of drug penetration in solid tumors. Front Oncol (2013) 0.83
Albumin modulates S1P delivery from red blood cells in perfused microvessels: mechanism of the protein effect. Am J Physiol Heart Circ Physiol (2014) 0.80
CpG expedites regression of local and systemic tumors when combined with activatable nanodelivery. J Control Release (2015) 0.79
Novel delivery approaches for cancer therapeutics. J Control Release (2015) 0.79
Ultrasound ablation enhances drug accumulation and survival in mammary carcinoma models. J Clin Invest (2015) 0.79
Selected Biomarkers Revealed Potential Skin Toxicity Caused by Certain Copper Compounds. Sci Rep (2016) 0.75
Intracellular trafficking of a pH-responsive drug metal complex. J Control Release (2016) 0.75
Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin. J Control Release (2017) 0.75
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul (2001) 6.59
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res (1994) 3.54
Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta (1993) 2.92
The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science (1982) 2.08
Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol (2008) 2.04
Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res (1999) 2.00
Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res (2005) 1.86
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J Pharm Sci (2008) 1.67
Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release (2009) 1.60
Combined Bcl-2/mammalian target of rapamycin inhibition leads to enhanced radiosensitization via induction of apoptosis and autophagy in non-small cell lung tumor xenograft model. Clin Cancer Res (2009) 1.53
Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res (2006) 1.39
A novel method to label preformed liposomes with 64Cu for positron emission tomography (PET) imaging. Bioconjug Chem (2008) 1.39
The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey. Chem Phys Lipids (1990) 1.31
Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. Biochim Biophys Acta (1998) 1.18
Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochim Biophys Acta (1985) 1.18
Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol (2005) 1.16
Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs. Pharm Res (1993) 1.12
Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem (2006) 1.05
Increased adriamycin levels in hepatic implants of rabbit Vx-2 carcinoma from regional infusion. Cancer Res (1988) 1.02
Formation of transition metal-doxorubicin complexes inside liposomes. Biochim Biophys Acta (2002) 1.00
Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim Biophys Acta (1995) 1.00
Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim Biophys Acta (2006) 0.99
Loading of amphipathic weak acids into liposomes in response to transmembrane calcium acetate gradients. Biochim Biophys Acta (1995) 0.97
Non-invasive monitoring of intra-tumor drug concentration and therapeutic response using optical spectroscopy. J Control Release (2009) 0.92
Transition metal-mediated liposomal encapsulation of irinotecan (CPT-11) stabilizes the drug in the therapeutically active lactone conformation. Pharm Res (2006) 0.90
Cholesterol transport from liposomal delivery vehicles. Biomaterials (2007) 0.89
Loading of doxorubicin into liposomes by forming Mn2+-drug complexes. Biochim Biophys Acta (1998) 0.87
Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese. J Control Release (2005) 0.87
Solution chemistry studies of adriamycin--iron complexes present in vivo. Eur J Cancer (1980) 0.85
Model simulation and experimental validation of intratumoral chemotherapy using multiple polymer implants. Med Biol Eng Comput (2008) 0.85
Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of doxorubicin entrapped in stable liposomes in the LOU/M Wsl rat. Cancer Res (1984) 0.85
Role of copper gluconate/triethanolamine in irinotecan encapsulation inside the liposomes. Int J Pharm (2007) 0.81
Nonenzymatic oxygen activation and stimulation of lipid peroxidation by doxorubicin-copper. Toxicol Appl Pharmacol (1986) 0.79
The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell (2005) 5.81
MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature (2004) 5.61
Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet (2009) 5.31
PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell (2003) 5.13
Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood (2002) 4.88
Architecture of ribonucleoprotein complexes in influenza A virus particles. Nature (2006) 4.52
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell (2002) 4.36
Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell (2006) 4.15
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet (2013) 3.87
Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell (2005) 3.68
Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci U S A (2003) 3.61
Epstein-Barr virus and virus human protein interaction maps. Proc Natl Acad Sci U S A (2007) 3.50
Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res (2004) 3.43
Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol (2013) 2.90
Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2002) 2.89
Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res (2004) 2.84
Novel genes derived from noncoding DNA in Drosophila melanogaster are frequently X-linked and exhibit testis-biased expression. Proc Natl Acad Sci U S A (2006) 2.84
Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression. Proc Natl Acad Sci U S A (2007) 2.64
The atomic structure of rice dwarf virus reveals the self-assembly mechanism of component proteins. Structure (2003) 2.53
Syngeneic mouse mammary carcinoma cell lines: two closely related cell lines with divergent metastatic behavior. Clin Exp Metastasis (2005) 2.52
Prostatic intraepithelial neoplasia in genetically engineered mice. Am J Pathol (2002) 2.48
Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer (2007) 2.41
The magnitude of radiation force on ultrasound contrast agents. J Acoust Soc Am (2002) 2.38
Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res (2002) 2.29
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev (2003) 2.27
Ultrasound contrast microbubbles in imaging and therapy: physical principles and engineering. Phys Med Biol (2009) 2.27
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol (2002) 2.26
Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol (2007) 2.23
Radiation-force assisted targeting facilitates ultrasonic molecular imaging. Mol Imaging (2004) 2.19
Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res (2003) 2.11
Direct observations of ultrasound microbubble contrast agent interaction with the microvessel wall. J Acoust Soc Am (2007) 2.11
Developmental context determines latency of MYC-induced tumorigenesis. PLoS Biol (2004) 2.05
A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials (2009) 2.04
A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics (2006) 2.03
Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A (2009) 2.01
Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug Chem (2010) 1.98
Acoustic response of compliable microvessels containing ultrasound contrast agents. Phys Med Biol (2006) 1.91
Targeted imaging using ultrasound. J Magn Reson Imaging (2002) 1.88
Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors. Cancer Cell (2010) 1.88
Enhancement of vascular permeability with low-frequency contrast-enhanced ultrasound in the chorioallantoic membrane model. Radiology (2007) 1.86
Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proc Natl Acad Sci U S A (2009) 1.82
ShcA signalling is essential for tumour progression in mouse models of human breast cancer. EMBO J (2008) 1.82
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol (2007) 1.81
A human breast cell model of preinvasive to invasive transition. Cancer Res (2008) 1.79
A method for radiation-force localized drug delivery using gas-filled lipospheres. IEEE Trans Ultrason Ferroelectr Freq Control (2004) 1.79
Motion corrected cadence CPS ultrasound for quantifying response to vasoactive drugs in a rat kidney model. Urology (2009) 1.78
Influence of lipid shell physicochemical properties on ultrasound-induced microbubble destruction. IEEE Trans Ultrason Ferroelectr Freq Control (2005) 1.77
Evidence for de novo evolution of testis-expressed genes in the Drosophila yakuba/Drosophila erecta clade. Genetics (2007) 1.75
"OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res (2012) 1.75
Therapeutic effects of paclitaxel-containing ultrasound contrast agents. Ultrasound Med Biol (2006) 1.75
Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol (2008) 1.74
Acoustically-active microbubbles conjugated to liposomes: characterization of a proposed drug delivery vehicle. J Control Release (2006) 1.70
Initial characterization of a dedicated breast PET/CT scanner during human imaging. J Nucl Med (2009) 1.68
Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol (2009) 1.68
Ultrasound radiation force enables targeted deposition of model drug carriers loaded on microbubbles. J Control Release (2005) 1.68
Somatic mutation of p53 leads to estrogen receptor alpha-positive and -negative mouse mammary tumors with high frequency of metastasis. Cancer Res (2004) 1.67
Nephrin strands contribute to a porous slit diaphragm scaffold as revealed by electron tomography. J Clin Invest (2004) 1.67
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. Proc Natl Acad Sci U S A (2013) 1.66
Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res (2013) 1.66
Ultrasound molecular imaging of tumor angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol (2011) 1.64
Airway wall thickness assessed using computed tomography and optical coherence tomography. Am J Respir Crit Care Med (2008) 1.64
High-mannose glycans are elevated during breast cancer progression. Mol Cell Proteomics (2010) 1.63
Sphingosine-1-phosphate lyase potentiates apoptosis via p53- and p38-dependent pathways and is down-regulated in colon cancer. Proc Natl Acad Sci U S A (2006) 1.63
Long-circulating liposomes radiolabeled with [18F]fluorodipalmitin ([18F]FDP). Nucl Med Biol (2007) 1.60
Enhanced in vivo bioluminescence imaging using liposomal luciferin delivery system. J Control Release (2009) 1.60
Maternal dioxin exposure combined with a diet high in fat increases mammary cancer incidence in mice. Environ Health Perspect (2010) 1.60
Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer. Cancer Res (2008) 1.59
PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev (2004) 1.58
Recently evolved genes identified from Drosophila yakuba and D. erecta accessory gland expressed sequence tags. Genetics (2005) 1.56
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas. Breast Cancer Res (2012) 1.56
T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res (2008) 1.54
Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res (2007) 1.54
SLITs suppress tumor growth in vivo by silencing Sdf1/Cxcr4 within breast epithelium. Cancer Res (2008) 1.52
Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res (2011) 1.52
Lateral phase separation in lipid-coated microbubbles. Langmuir (2006) 1.52
E mu-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood (2003) 1.51
Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Res (2005) 1.50
Validation: the new challenge for pathology. Toxicol Pathol (2004) 1.50
Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells. Mol Imaging (2004) 1.49
EMT tumorigenesis in the mouse mammary gland. Lab Invest (2007) 1.47
A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci U S A (2004) 1.47
Targeted imaging using ultrasound contrast agents. Progess and opportunities for clinical and research applications. IEEE Eng Med Biol Mag (2004) 1.46
Activation of beta -catenin signaling in differentiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc Natl Acad Sci U S A (2002) 1.44
Essential elements of the capsid protein for self-assembly into empty virus-like particles of hepatitis E virus. J Virol (2005) 1.43
Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene (2002) 1.43